Clinical Trial: A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title:

Brief Summary: To evaluate the efficacy of voloxicimab when administered at 15 mg/kg qwk in subjects with platinum-resistant, advanced epithelial ovarian cancer or primary peritoneal cancer.

Detailed Summary:
Sponsor: Facet Biotech

Current Primary Outcome: Efficacy as measured by objective response rate (ORR). Tumor response based on RECIST criteria. [ Time Frame: Baseline, and every 8 weeks on study ]

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Facet Biotech

Dates:
Date Received: August 14, 2007
Date Started: August 2007
Date Completion:
Last Updated: August 21, 2012
Last Verified: August 2012